Dual Inhibition of Pirarubicin-Induced AKT and ERK Activations by Phenformin Sensitively Suppresses Bladder Cancer Growth
出版年份 2019 全文链接
标题
Dual Inhibition of Pirarubicin-Induced AKT and ERK Activations by Phenformin Sensitively Suppresses Bladder Cancer Growth
作者
关键词
-
出版物
Frontiers in Pharmacology
Volume 10, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2019-10-08
DOI
10.3389/fphar.2019.01159
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Dual inhibitors of RAF-MEK-ERK and PI3K-PDK1-AKT pathways: Design, synthesis and preliminary anticancer activity studies of 3-substituted-5-(phenylamino) indolone derivatives
- (2019) Zutao Yu et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Dual inhibition of Akt and ERK signaling induces cell senescence in triple-negative breast cancer
- (2019) Qiang He et al. CANCER LETTERS
- Phenformin, But Not Metformin, Delays Development of T Cell Acute Lymphoblastic Leukemia/Lymphoma via Cell-Autonomous AMPK Activation
- (2019) Diana Vara-Ciruelos et al. Cell Reports
- Update on early instillation of chemotherapy after transurethral resection of non-muscle-invasive bladder cancer
- (2018) Willem Oosterlinck et al. Expert Review of Anticancer Therapy
- Metformin as geroprotector: experimental and clinical evidence
- (2018) Veronika Piskovatska et al. BIOGERONTOLOGY
- SH2B1 promotes NSCLC cell proliferation through PI3K/Akt/mTOR signaling cascade
- (2018) Shaoqiang Wang et al. Cancer Cell International
- Molecular Subtypes of Urothelial Bladder Cancer: Results from a Meta-cohort Analysis of 2411 Tumors
- (2018) Tuan Zea Tan et al. EUROPEAN UROLOGY
- Crosstalk between Raf-MEK-ERK and PI3K-Akt-GSK3β signaling networks promotes chemoresistance, invasion/migration and stemness via expression of CD44 variants (v4 and v6) in oral cancer
- (2018) Tanushree Kashyap et al. ORAL ONCOLOGY
- EAU Guidelines on Non–Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016
- (2017) Marko Babjuk et al. EUROPEAN UROLOGY
- Re: Systematic Review and Individual Patient Data Meta-Analysis of Randomized Trials Comparing a Single Immediate Instillation of Chemotherapy after Transurethral Resection with Transurethral Resection Alone in Patients with Stage pTa-pT1 Urothelial Carcinoma of the Bladder: Which Patients Benefit from the Instillation?
- (2017) Sam S. Chang JOURNAL OF UROLOGY
- Metformin – its potential anti-cancer and anti-aging effects
- (2017) Monika Podhorecka et al. Postepy Higieny I Medycyny Doswiadczalnej
- Phenformin inhibits growth and epithelial-mesenchymal transition of ErbB2-overexpressing breast cancer cells through targeting the IGF1R pathway
- (2017) Zhiying Guo et al. Oncotarget
- The mutational spectrum of HRAS, KRAS, NRAS and FGFR3 genes in bladder cancer
- (2017) Slah Ouerhani et al. Cancer Biomarkers
- Bladder Cancer
- (2017) Peter E. Clark et al. Journal of the National Comprehensive Cancer Network
- Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression
- (2016) Tikvah K. Hayes et al. CANCER CELL
- Are Metformin Doses Used in Murine Cancer Models Clinically Relevant?
- (2016) Navdeep S. Chandel et al. Cell Metabolism
- miR-222 attenuates cisplatin-induced cell death by targeting the PPP2R2A/Akt/mTOR Axis in bladder cancer cells
- (2016) Li-Ping Zeng et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- High efficacy of intravesical treatment of metformin on bladder cancer in preclinical model
- (2016) Mei Peng et al. Oncotarget
- Single, immediate postoperative instillation of chemotherapy in non-muscle invasive bladder cancer: a systematic review and network meta-analysis of randomized clinical trials using different drugs
- (2016) Minyong Kang et al. Oncotarget
- The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (Duvelisib), overcomes signals from the PI3K/AKT/S6 pathway and promotes apoptosis in CLL
- (2015) K Balakrishnan et al. LEUKEMIA
- Therapy-induced tumour secretomes promote resistance and tumour progression
- (2015) Anna C. Obenauf et al. NATURE
- Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations
- (2015) L. G. Ahronian et al. Cancer Discovery
- MERIT40 Is an Akt Substrate that Promotes Resolution of DNA Damage Induced by Chemotherapy
- (2015) Kristin K. Brown et al. Cell Reports
- Oncobiguanides: Paracelsus’ law and nonconventional routes for administering diabetobiguanides for cancer treatment
- (2015) Javier A. Menendez et al. Oncotarget
- Mutant PIK3CA controls DUSP1-dependent ERK 1/2 activity to confer response to AKT target therapy
- (2014) A Sathe et al. BRITISH JOURNAL OF CANCER
- Role of AKT signaling in DNA repair and clinical response to cancer therapy
- (2014) Q. Liu et al. NEURO-ONCOLOGY
- The granulocyte macrophage–colony stimulating factor surface modified MB49 bladder cancer stem cells vaccine against metastatic bladder cancer
- (2014) Yong-tong Zhu et al. Stem Cell Research
- PI3K/AKT pathway activation in bladder carcinogenesis
- (2013) Julien Calderaro et al. INTERNATIONAL JOURNAL OF CANCER
- Regulation of mTORC1 and its impact on gene expression at a glance
- (2013) M. Laplante et al. JOURNAL OF CELL SCIENCE
- Prospective Randomized Phase II Trial of a Single Early Intravesical Instillation of Pirarubicin (THP) in the Prevention of Bladder Recurrence After Nephroureterectomy for Upper Urinary Tract Urothelial Carcinoma: The THP Monotherapy Study Group Trial
- (2013) Akihiro Ito et al. JOURNAL OF CLINICAL ONCOLOGY
- Diphtheria Toxin-Epidermal Growth Factor Fusion Protein DAB389EGF for the Treatment of Bladder Cancer
- (2012) X. Yang et al. CLINICAL CANCER RESEARCH
- Resistance to BRAF Inhibition in BRAF-Mutant Colon Cancer Can Be Overcome with PI3K Inhibition or Demethylating Agents
- (2012) M. Mao et al. CLINICAL CANCER RESEARCH
- Comprehensive molecular portraits of human breast tumours
- (2012) Daniel C. Koboldt et al. NATURE
- ERK and Akt signaling pathways function through parallel mechanisms to promote mTORC1 signaling
- (2011) Jeremiah N. Winter et al. AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY
- The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation
- (2011) Michelle C. Mendoza et al. TRENDS IN BIOCHEMICAL SCIENCES
- MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted Drugs In vitro and In vivo
- (2010) H. Hirai et al. MOLECULAR CANCER THERAPEUTICS
- Molecular pathways of urothelial development and bladder tumorigenesis
- (2010) Mireia Castillo-Martin et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Recurrence and Progression of Disease in Non–Muscle-Invasive Bladder Cancer: From Epidemiology to Treatment Strategy
- (2009) Bas W.G. van Rhijn et al. EUROPEAN UROLOGY
- Molecular Pathogenesis and Diagnostics of Bladder Cancer
- (2008) Anirban P. Mitra et al. Annual Review of Pathology-Mechanisms of Disease
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started